Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

BZLF1 peptide vaccine OSU-2131

A cancer preventive vaccine composed of the synthetic peptide RAKFKQLL, which is derived from the Epstein-Barr virus (EBV) immediate-early protein and transcriptional activator BZLF1, and complexed with the recombinant human heat shock protein Hsc70, with potential immunoactivating and antineoplastic activities. Upon subcutaneous administration of the BZLF1 peptide vaccine OSU-2131, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against BZLF1-expressing and EBV-infected cells. This may prevent EBV infections and the development of EBV-driven cancer cells. The Hsc70 may enhance the T-cell responses against the BZLF1 peptide.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:BZLF1-specific peptide vaccine OSU-2131
rh-Hsc70-BZLF1 peptide complex vaccine OSU-2131
Code name:OSU 2131
OSU-2131
OSU2131
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search